Reata Pharmaceuticals Inc.

Our Technologies

Reata has active clinical, preclinical, and internal discovery programs in many significant disease areas. We focus on molecular pathways that regulate cellular metabolism, inflammation, and the response to cellular stress in serious and life-threatening diseases that have limited or no approved therapies.

Nrf2 Activators

©Reata Pharmaceuticals, Inc.
Kelch domain of Keap1
PDB Code 2FLU

Nrf2 is a transcription factor that promotes the resolution of inflammation by restoring mitochondrial function, reducing oxidative stress, and inhibiting pro-inflammatory signaling (1-3).

HSP90 Modulators

©Reata Pharmaceuticals, Inc.
Middle segment of HSP90
PDB Code 1USV

We are developing a novel class of molecules that target pathways involved in the cellular stress response. Our lead product candidate, Cemdomespib, and related analogs have shown promising effects in animal models of neurological disease. Cemdomespib is in development for Diabetic Peripheral Neuropathic Pain.

Our Pipeline

Reata’s development programs now have an approved product in addition to creating a robust pipeline of drug candidates for the treatment of serious, life-threatening diseases.

Preclinical

Phase 1

Phase 2

Pivotal

Regulatory Review

FDA Approved

Neurology

Friedreich's Ataxia | SKYCLARYS^a Friedreich's Ataxia
SKYCLARYS^a

Follow the links to:

Learn more about FA.

Friedreich's Ataxia | Omaveloxolone in Europe^b Friedreich's Ataxia
Omaveloxolone in Europe^b

Follow the links to:

Learn more about FA.

DPNP^c | Cemdomespib DPNP^c
Cemdomespib

Follow the links to:

Learn more about DPNP.
Learn about Cemdomespib.

Nrf2 Activator | RTA 415 Nrf2 Activator
RTA 415

Follow the links to:

Learn about our Nrf2 activators.

Nrf2 Activator | RTA 417 Nrf2 Activator
RTA 417

Follow the links to:

Learn about our Nrf2 activators.

^aSKYCLARYS (omaveloxolone) is approved by the U.S. FDA and not approved by any other regulatory authority outside the U.S. ^bMarketing Authorisation Application (MAA) submitted in 4Q22 in Europe. ^cDiabetic peripheral neuropathic pain (DPNP). Reata plans to initiate a Phase 2 trial of Cemdomespib in patients with DPNP in the third quarter of 2023.

Cemdomespib, RTA 415, and RTA 417 are investigational drugs. Safety and efficacy have not been established by any agency.

References

Yamamoto, M., Kensler, T. W., and Motohashi, H. (2018) The KEAP1-NRF2 System: a Thiol-Based Sensor-Effector Apparatus for Maintaining Redox Homeostasis. Physiol Rev 98, 1169-1203
Hayes, J. D., and Dinkova-Kostova, A. T. (2014) The Nrf2 regulatory network provides an interface between redox and intermediary metabolism. Trends Biochem. Sci 39, 199-218
Holmstrom, K. M., Kostov, R. V., and Dinkova-Kostova, A. T. (2016) The multifaceted role of Nrf2 in mitochondrial function. Curr Opin Toxicol 1, 80-91

Our Science

Our Technologies

Nrf2 Activators

HSP90 Modulators

Our Pipeline

References